The Only Companies Making Profits In China Are The Nucleic Acid Testing Companies

According to a report on September 13th, semi-annual reports of nearly 5,000 A-share companies in mainland China had stated that real estate, transportation, social services, electronics, and automobile industries related to people’s livelihood are in a state of the huge decline. Only the controversial Nucleic Acid Testing sector has risen to become the champion of A-shares this year, becoming the latest pillar industry of the collapsing economy of communist China.

 Since the second half of 2021, Nucleic Acid Testing NAT has become the protagonist of Chinese residents’ daily life. Starting from March this year, 20 million residents in Shenzhen were required to take a NAT every 24 hours, and no one was allowed to work or travel without a negative NAT report. At a price of 4-6 yuan per NAT, a city like Shenzhen can create approximately 100 million yuan in revenue, 100 million – and its only for one city– for NAT companies every day.

 The disclosed data shows that six listed companies in the NAT sector, achieved total revenue of 24.7 billion yuan in the first half of 2022, with a stunning net profit of 7.3 billion in just one year. With, KingMed Diagnostics, Daan gene, and LabWay having reached net profit growth of 55%, 64.6%, and a staggering 338% respectively.